Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

PURPOSE Although docetaxel is not recommended when managing men with unfavorable-risk prostate cancer (PC) given negative or inconclusive results from previous randomized trials, unstudied benefits may exist. METHODS Between September 21, 2005, and January 13, 2015, we randomly assigned 350 men 1:1 with T1c-4N0M0 unfavorable-risk PC to receive radiation therapy (RT) and androgen deprivation...

  • While some therapies seem to have benefit earlier and earlier in the disease course, docetaxel doesn’t seem to be one of them. No benefit in OS when docetaxel added to radiation and ADT in unfavorable risk prostate cancer.